enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Lilly says weight loss drug cuts heart failure risk by ... - AOL

   www.aol.com/news/lilly-says-weight-loss-drug...

   The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss ...

3. What Are GLP-1 Medications & Who Should Use Them? Here ... - AOL

   www.aol.com/glp-1-medications-them-heres...

   The prescriber recommendations for weight loss include “those with a BMI of 30 or above or a BMI of at least 27 and a coexisting condition such as diabetes, heart disease or sleep apnea may be ...

4. Popular weight loss drug found to reduce risk of heart ... - AOL

   www.aol.com/popular-weight-loss-drug-found...

   Taking a weight loss drug may also help reduce the risk of heart attack, stroke and cardiac death, data shows. Wegovy, a drug approved by the U.S. Food and Drug Administration to treat obesity ...

5. 15 Alternatives to Ozempic for Weight Loss - AOL

   www.aol.com/15-alternatives-ozempic-weight-loss...

   Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss — when a drug is prescribed for something it’s not approved for.

6. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.